January 22, 2019
Article
Through ongoing quarterly targeted medication counseling follow-up sessions, the pharmacist may identify ART noncompliance.
November 15, 2018
On August 23, 2018, the FDA approved lanadelumab-flyo (Takhzyro; Shire) for the prophylaxis treatment and prevention of hereditary angioedema (HAE) in patients 12 years or older.
July 19, 2018
Based on 2017 FDA research, the delayed market launch of nine biosimilars represented $4.5 billion in potential savings.